Brostallicin

Drug Profile

Brostallicin

Alternative Names: PNU-166196; PNU-166196A; SMi-BX1

Latest Information Update: 31 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacia Corporation
  • Developer CTI BioPharma; National Cancer Institute (USA); Systems Medicine
  • Class Antineoplastics; DNA-binding proteins; Guanidines; Pyrroles; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Soft tissue sarcoma

Most Recent Events

  • 30 May 2014 Cell Therapeutics is now called CTI BioPharma
  • 01 Jun 2013 Final efficacy data from a Phase-II trial in Breast cancer (Metastatic disease, Combination therapy) presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
  • 05 Dec 2012 Interim efficacy and safety data from a phase II trial in Breast cancer presented at the 35th Annual San Antonio Breast Cancer Symposium (SABCS-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top